APA Alıntı

Herold, K. C., Gitelman, S., Greenbaum, C., Puck, J., Hagopian, W., Gottlieb, P., . . . Bluestone, J. A. (2009). Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years.

Chicago Stili Alıntı

Herold, Kevan C., et al. Treatment of Patients With New Onset Type 1 Diabetes With a Single Course of Anti-CD3 MAb Teplizumab Preserves Insulin Production for Up to 5 Years. 2009.

MLA Alıntı

Herold, Kevan C., et al. Treatment of Patients With New Onset Type 1 Diabetes With a Single Course of Anti-CD3 MAb Teplizumab Preserves Insulin Production for Up to 5 Years. 2009.